



## Clinical trial results:

**Evaluation of the clinical and echographic response to Apremilast through clinical evaluation and through a joint-periarticular-nail echographic index in patients with active psoriatic arthritis.**

### Summary

EudraCT number	2017-000901-19
Trial protocol	ES
Global end of trial date	23 September 2021

### Results information

Result version number	v1 (current)
This version publication date	15 December 2022
First version publication date	15 December 2022

### Trial information

#### Trial identification

Sponsor protocol code	PSAPI006421
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
Sponsor organisation address	Passeig Vall Hebron 119-129, Barcelona, Spain, 08035
Public contact	Juan José de agustín de Oro, Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), 34 934893000,
Scientific contact	Juan José de agustín de Oro, Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), 34 934894189/606245743,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	01 June 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 September 2021
Global end of trial reached?	Yes
Global end of trial date	23 September 2021
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

To obtain a 20% reduction in the echographic index at 12 months after the introduction of Apremilast in study patients

Protection of trial subjects:

There is no need to have special measurements to protect patients in this assay, since no pain or stress is expected

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 March 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Spain: 46
Worldwide total number of subjects	46
EEA total number of subjects	46

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	46
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The inclusion criteria are:

- Adults  $\geq 18$  years old with Psoriatic Arthritis with involvement of the hands and /or feet with active clinical disease
- Presenting  $>2$  synovitis and  $>1$  enthesis by ultrasound

The exclusion criteria are:

- Concomitant treatment with methotrexate or flunomide or other DMARS
- Previous or current use of biologic therap

### Pre-assignment period milestones

Number of subjects started	46
Number of subjects completed	46

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Experimental
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Apremilast
Investigational medicinal product code	
Other name	Otezla
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

30 mg capsules twice a day for 12 months

Number of subjects in period 1	Experimental
Started	46
Completed	26
Not completed	20
Adverse event, non-fatal	6
Inform consent withdrawal	3
Lost to follow-up	3
Lack of efficacy	8



## Baseline characteristics

### Reporting groups

Reporting group title	Overall trial
Reporting group description:	
Adults ≥ 18 years old with Psoriatic Arthritis with involvement of the hands and /or feet with active clinical disease, presenting >2 synovitis and >1 enthesis by ultrasound	

Reporting group values	Overall trial	Total	
Number of subjects	46	46	
Age categorical			
Units: Subjects			
Adults (18-64 years)	46	46	
Age continuous			
Units: years			
arithmetic mean	51.3		
standard deviation	± 10.4	-	
Gender categorical			
Units: Subjects			
Female	19	19	
Male	27	27	

### Subject analysis sets

Subject analysis set title	Full study
Subject analysis set type	Full analysis
Subject analysis set description:	
All the patients who started the treatment are included	

Reporting group values	Full study		
Number of subjects	46		
Age categorical			
Units: Subjects			
Adults (18-64 years)	46		
Age continuous			
Units: years			
arithmetic mean	51.3		
standard deviation	± 10.4		
Gender categorical			
Units: Subjects			
Female	19		
Male	27		

## End points

### End points reporting groups

Reporting group title	Experimental
Reporting group description: -	
Subject analysis set title	Full study
Subject analysis set type	Full analysis
Subject analysis set description:	
All the patients who started the treatment are included	

### Primary: Change in ultrasound index

End point title	Change in ultrasound index
End point description:	
End point type	Primary
End point timeframe:	
At 12 months after introduction of IMP	

End point values	Experimental	Full study		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	26	26		
Units: Percentage				
number (not applicable)	-52.3	-52.3		

### Statistical analyses

Statistical analysis title	Treatment
Comparison groups	Experimental v Full study
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Mean difference (net)
Point estimate	-50
Confidence interval	
level	95 %
sides	2-sided
lower limit	-66
upper limit	-38.5
Variability estimate	Standard deviation

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

End of study

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25
--------------------	----

### Reporting groups

Reporting group title	Treatment group
-----------------------	-----------------

Reporting group description: -

Serious adverse events	Treatment group		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 46 (2.17%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Gastrointestinal disorders			
Diverticulitis			
subjects affected / exposed	1 / 46 (2.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Treatment group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 46 (76.09%)		
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 46 (2.17%)		
occurrences (all)	1		
Nervous system disorders			
Cefalea			
subjects affected / exposed	4 / 46 (8.70%)		
occurrences (all)	4		
General disorders and administration site conditions			

Transaminases increased subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1		
Social circumstances Depression subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2		
Insomnia subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	15 / 46 (32.61%) 16		
Pyrosis subjects affected / exposed occurrences (all)	3 / 46 (6.52%) 3		
Nausea subjects affected / exposed occurrences (all)	3 / 46 (6.52%) 3		
Abdominal pain subjects affected / exposed occurrences (all)	5 / 46 (10.87%) 5		
Vomiting subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2		
Dyspepsia subjects affected / exposed occurrences (all)	2 / 46 (4.35%) 2		
Skin and subcutaneous tissue disorders Hair disorder subjects affected / exposed occurrences (all)	1 / 46 (2.17%) 1		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 May 2018	Because recruitment is lower than expected, it is decided to include a new center (Hospital del Mar).
19 July 2019	The sample size was recalculated due to low recruitment (at that time, a total of 38 patients had been included). An effect of 5% (range of reduction between 15% and 25%) was assumed. The effect size 0.5 is reached with a deviation of 0.1 or greater. Therefore, it was decided that with a size of 45, results with significant values could be obtained.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported